NU6140 is primarily recognized for its potential in cancer research, particularly as a CDK2 inhibitor. It has shown promise in inhibiting the proliferation of cancer cells by targeting cyclin-dependent kinase 2, which plays a critical role in cell cycle regulation. This makes it a valuable tool in studying tumor growth and developing therapeutic strategies for various cancers, such as ovarian and breast cancer. Additionally, it is used in laboratory settings to explore mechanisms of cell cycle control and apoptosis, providing insights into cellular pathways that could be targeted for cancer treatment. Its application extends to preclinical studies, where it helps evaluate the efficacy of CDK2 inhibition in reducing tumor progression.